1. A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC) 
Giorgio Arcangeli, Stefano Arcangeli, Lidia Strigari 
Critical Reviews in Oncology / Hematology 
Volume 94, Issue 1, Pages (April 2015)
DOI: /j.critrevonc
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

2. Fig. 1
Flow of identification and inclusion of trials as recommended by PRISMA [5].
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

3. Fig. 2
(a) Cumulative results from all evaluated trials; in parentheses is the number of patients evaluated for each outcome. (b) Forest plot of HRs and 95% CIs of outcomes comparing continuous vs. split treatment course in all evaluated patients.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

4. Fig. 3
(a) CR and 5-year OS rates in patients with T2 or >T2 tumour stages. (b) Forest plot of HRs and 95%CIs of CR and 5-year OS rates comparing continuous vs. split treatment course in patients with T2 or >T2 tumour stages.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

5. Fig. 4
CR and 5-year OS rates in patients with or without hydronephrosis.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

6. Fig. 5
Diagram showing (a) CR and (b) 5-year OS rates as a function of EQD2 in all trials of continuous and split treatment course. In the split treatment, CR rate was plotted as a function of dose delivered by induction CRT course, while 5-year OS rate was plotted as a function of dose delivered by both induction and consolidation CRT courses also for patients undergone to SC.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

7. Fig. 6
Forest plot of HRs and 95%CIs of CR and 5-year OS rates comparing continuous vs. split treatment course in patients treated with CP alone or CP plus other drugs.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions

8. Fig. 7
(a) CR and 5-year OS rates in patients receiving neoadjuvant chemotherapy (NADCT+) or not (NADCT−). (b) Forest plot of HRs and 95%CIs of CR, cystectomy and 5-year OS rates comparing continuous vs. split treatment course in patients receiving or not receiving NACT.
Critical Reviews in Oncology / Hematology  , DOI: ( /j.critrevonc )
Copyright © 2014 Elsevier Ireland Ltd Terms and Conditions